Methods and compounds for enhancing anti-cancer therapy
OwnerDouglas Kim Graham, Rachel Linger +5inventors
InventorsDouglas Kim Graham, Rachel Linger, Deborah Deryckere, Susan Louise Sather, Amy Keating, Grace Kim, Luis Brandao
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating neoplastic disorders in a mammal through the inhibition of Mer and/or AxI receptor tyrosine kinases as well as compounds and compositions useful for inhibiting these kinases in these methods. These treatment methods may be combined with the administration of one or more chemo therapeutic agent(s) to enhance the efficacy or minimize the toxicities of the chemotherapeutic agent(s).
Claims35
A method of preventing or treating a neoplastic disorder in a mammal comprising inhibiting a receptor tyrosine kinase selected from the group consisting of Axl, Mer and Tyro-3 in the mammal.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of overcoming resistance of a neoplastic cell to a chemotherapeutic drug comprising inhibiting a receptor tyrosine kinase of the cell selected from the group consisting of Axl, Mer and Tyro-3.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating cancer in a mammal comprising:
- a. administering to the mammal a fusion protein comprising a Fc region of a human antibody fused with a protein selected from the group consisting of at least a portion of an extracellular domain of Axl receptor tyrosine kinase receptor and at least a portion of an extracellular domain of Mer receptor tyrosine kinase receptor;
- and,
- b. administering to the mammal a chemotherapeutic drug selected from the group consisting of 6-mercaptopurine, etoposide, adriamycin, vincristine and methotrexate.
A method of treating cancer in a mammal comprising:
- a. administering to the mammal an antibody that recognizes an epitope on the extracellular domain of at least one of an Axl and Mer receptor tyrosine kinase;
- and,
- b. administering to the mammal a chemotherapeutic drug selected from the group consisting of 6-mercaptopurine, etoposide, adriamycin, vincristine and methotrexate.
35-49. (canceled)
Dependencies are inferred from the claim text.